CURRICULUM VITAE David D. Dore, PharmD, PhD

CONTACT INFORMATION Office:

Optum Epidemiology 950 Winter Street Suite 3800 Waltham, MA Tel: 401-741-4154 [email protected] [email protected]

Home:

20 Rebecca Road S. Dartmouth, MA 02748

EDUCATION 2008

PhD, Epidemiology (Advisor: Kate L. Lapane, PhD) Brown Medical School, Providence, RI Dissertation: “Benefits and Consequences of Drug Therapy in the Elderly”

2006−2007

Post-doctoral Fellowship (Mentor: Vincent Mor, PhD) Center for Gerontology and Health Care Research Brown Medical School, Providence, RI

2004

PharmD University of Rhode Island, Kingston, RI

PRIMARY PROFESSIONAL APPOINTMENT 2014−present

Vice President of Epidemiology and Principal Epidemiologist, Optum

ADDITIONAL PROFESSIONAL APPOINTMENTS 2014−present

Adjunct Assistant Professor of Health Services, Policy & Practice Brown University School of Public Health

2013−present

Member, Data and Safety Monitoring Board, “Levonorgestrel Intrauterine System versus Combined Oral Contraceptives for Heavy Menses (1R01HD074751-01, NICHD)”. PI: Kristen A. Matteson, MD, MPH

2013−present

Faculty, Brown University Executive Master of Healthcare Leadership

2012−present

Investigator, Health Services, Research & Development Service Providence Veterans Affairs Medical Center

PREVIOUS PROFESSIONAL APPOINTMENTS

Updated April 2014

Page 1 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

2011−2014

Assistant Professor of Health Services, Policy, and Practice (tenure track) Brown University School of Public Health

2011−2014

Assistant Professor of Epidemiology Brown University School of Public Health

2011−2014

Faculty Investigator Center for Gerontology and Health Care Research Brown University School of Public Health

2011−2014

Senior Consultant, Epidemiology Optum Epidemiology (formerly i3 Drug Safety/Innovus)

2010−2011

Senior Scientist Optum Epidemiology (formerly i3 Drug Safety/Innovus), Waltham, MA

2007−2010

Epidemiologist III (Senior Epidemiologist) i3 Drug Safety, Waltham, MA

2008−2011

Adjunct Assistant Professor of Community Health Department of Community Health The Warren Alpert Medical School of Brown University Providence, RI

2007

Consultant, Pharmacoepidemiology i3 Drug Safety, Waltham, MA

2006−2007

Consultant Pfizer Safety and Risk Management, New London, CT

2006

Per Diem Staff Pharmacist Stop and Shop Pharmacy, Rhode Island

2005−2006

Research Fellow in Pharmacoepidemiology and Therapeutic Risk Management Pfizer Safety and Risk Management, New London, CT

2004−2005

Floating Staff Pharmacist Brooks-Eckerd Pharmacy (now Rite Aid), Rhode Island

COMMUNITY SERVICE 2013−present

Alternate Member, Zoning Board of Appeals, Town of Dartmouth, MA (appointed by Select Board)

HONORS AND AWARDS 2011

Updated April 2014

Team Member, Ingenix First Place Innovation Award—Ingenix (Optum) Natural History of Disease Application

Page 2 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

2010

Ingenix (Optum) President’s Award Recipient

2006−2010, 2014

Annals of Internal Medicine Outstanding Reviewer Recognition Reviews graded by editors to be in the top 10% of all peer reviews (2009)

2004

Rhode Island Pharmacists Association Student Service Award

2004

American Pharmacists Association Mortar and Pestle Professionalism Award

2004

University of Rhode Island College of Pharmacy Excellence in Research Award

2004

Kappa Psi Pharmaceutical Fraternity Brother of the Year Award

2002

Kappa Psi Pharmaceutical Fraternity Scholarship Honors

TEACHING EXPERIENCE Courses 2014

Co-instructor: EHML2030 “Data-Driven Decision Making: The Structure, Conduct, Review, and Evaluation of Research,” an online course offered as part of the Brown Executive Master of Healthcare Leadership.

Spring 2013

Co-instructor: PHP2120 “Introduction to Epidemiologic Research Methods,” a semester-long course offered as part of the Brown University-Pfizer Master of Arts Program in Biology

2012−present Lead Instructor: PHP2490 “Methods in Pharmacoepidemiology,” a semester-long course for masters and doctoral students on advanced pharmacoepidemiologic methods. Brown University School of Public Health 2011−2013

Section Leader: PHP2507 “Introduction to Biostatistics,” a semester-long analytic internship course for students in the masters of public health program. Brown University School of Public Health

2009−present Lead Instructor: PPH2440 “Introduction to Pharmacoepidemiology,” a semester-long course for clinicians, masters students, and doctoral students in epidemiology and health services research covering topics related to studying outcomes of medical interventions. Brown University School of Public Health 2008−2012

Section Leader: Biol3650 C IMS-II, “Epidemiology/Quantitative Reasoning” 1st and 2nd year medical curriculum, Brown Medical School

2007

Guest Lecturer: PPH2410C “Pharmacoepidemiology” Program in Public Health, Brown Medical School

2006−2007

Guest Lecturer: PPPI1700K “Health Policy Challenges” Department of Public Policy, Brown University

Updated April 2014

Page 3 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

Special Training Received 2005

Teaching Certificate I Brown University Sheridan Center for Teaching and Learning in Higher Education Awarded after participation in the Sheridan Teaching Seminar lectures and workshops, participation in a departmental micro-teaching session, completion of an individual teaching consultation, and submission of a formal summary evaluation

Advising and Mentoring 2013−present Committee Member, Kevin Fain, JD, MPH (PhD, epidemiology). Title: “Prescription Opioid Use in Elderly Nursing Home Residents.” Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. (with Carlos Castillo-Salgado, MD, JD, MPH, DrPH [Chair] and G. Caleb Alexander, MD, MS) 2013−present Primary Thesis Advisor, Wei Lu, PhD, MPH candidate, Brown University Master of Public Health Program. Title: “Persistence on Treatment with GLP-1 Receptor Agonists and DPP-4 Inhibitors in Type 2 Diabetes Mellitus” (with Ira Wilson, MD, MSc) 2013−present Primary Thesis Advisor, Catherine Rogers, MPH candidate, Brown University Master of Public Health Program. Title: “Pediatricians and Parents’ Vaccine Hesitancy—An Exploration of Processes in Rhode Island” (with Melissa Clark, PhD) 2012−present Committee Member, Valery Danilack (PhD, epidemiology). Title: “Understanding the Effect of Labor Induction on the Risk of Cesarean Delivery” Department of Epidemiology, Brown University School of Public Health. (with David Savitz, PhD [chair], Elizabeth Triche, PhD, and Maureen Phipps, MD, MPH) 2012−present Primary Thesis Advisor, Katie Haron, MPH candidate, Brown University Master of Public Health Program. Title: “Case-crossover study of ADHD treatments and occurrence of migraine” (with Joseph Braun, MPSH, PhD) 2012−present Committee Member, Michael Lopez, PhD candidate (PhD, biostatistics). Title: “Treatment choice for aging population: Causal inference with multiple treatments.” Department of Biostatistics, Brown University School of Public Health (with Roee Gutman, PhD [chair], Joseph Hogan, ScD, and Vincent Mor, PhD) Awarded Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) 2012−present Committee Member, Nina Joyce, MPH (PhD, epidemiology). Title: TBD Dissertation on lipid lowering therapy for pediatric familial hypercholesterolemia. Department of Epidemiology, Brown University School of Public Health (with Greg Wellenius, ScD [chair] and Justin Zachariah, MD, MPH) Awarded American Heart Association Pre-doctoral Fellowship 2012−present Primary advisor for cohort of MPH students, Brown University Master of Public Health Program

Updated April 2014

Page 4 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

2012−2013

Primary Thesis Advisor, Efstathios Michalopoulos, MPH candidate, Brown University Master of Public Health Program. Title: “Prescription Patterns and Costs Associated with Treatment of Acute Depressive Episodes and Manic Episodes Associated with Bipolar-I Disorder (BD-1) Among Commercially Insured Patients.” Brown University School of Public Health (with Amal Trivedi, MD, MPH and Brady Case, MD)

2011−2013

Committee Chair, Danya Qato, PharmD, MPH, PhD (PhD, health services research). Title: “Elucidating the Role of Patients, Providers, and Policies in Predicting (mis)Use of High-Risk Prescription Medications.” Department of Health Services, Policy, & Practice, Brown University School of Public Health. (with Amal Trivedi, MD, MPH and Vincent Mor, PhD)

2011−present Committee Chair, Kade Etter, PhD candidate (PhD, health services research). Title: “The Effect Device Characteristics on the Rate of Total Hip and Knee Replacement Revisions in the Veterans Administration (VA) Healthcare System.” Department of Health Services, Policy, & Practice, Brown University School of Public Health (with Ira Wilson, MD, MSc, Linda Resnik, PT, PhD, Art Sedrakyan, MD, PhD, and Roee Gutman, PhD) Awarded AHRQ Dissertation Grant 2011−2012

Committee Member, Alicia Cooper, PhD (health services research). Title: “Predictors and consequences of inappropriate drug prescribing among the elderly.” Department of Health Services, Policy, & Practice, Brown University. (with Amal Trivedi, MD, MPH [chair], Lewis Kazis, ScD, and Vincent Mor, PhD) Winner, AcademyHealth's Outstanding Dissertation Award 2013

2009−2011

Committee Member, Shirley V. Wang, PhD (epidemiology). Title: “Evaluating the role of antipsychotic use as a trigger for ischemic stroke: application and extension of selfcontrolled designs.” Department of Community Health, Brown University. (with Stephen Buka, ScD [chair], Crystal Linkletter, PhD, Vincent Mor, PhD, and Malcolm Maclure, ScD)

PROFESSIONAL LICENSE 2004−present

Registered Pharmacist, Rhode Island (RPH04437)

ACADEMIC SERVICE AND PROFESSIONAL AFFILIATIONS 2014−present

Member, International Society for Pharmaceutical Outcomes Research (ISPOR)

2013−2014

Professional Member, American Heart Association

2013−present

Member, American Association for the Advancement of Science

2012−2013

Member, Association of Rheumatology Health Professionals

Updated April 2014

Page 5 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

2011

Member, Special Emphasis Panel for review of pilot project grant applications for the Patient-centered Outcomes Research Institute (PCORI)

2011

Member, Faculty Search Committee. Department of Health Services, Policy, & Practice, Brown University

2011−2013

Member, Admissions Committee Brown University Doctoral Program in Health Services Research

2007

Proposal Reviewer: Health, Welfare, and Food Bureau. The People’s Republic of China (Hong Kong Administrative Region).

2006−2007

Member, American Public Health Association

2006−2008

Member, AcademyHealth

2005−present

Member, International Society for Pharmacoepidemiology (ISPE); Specific Roles: • Education Committee (2010−Present); • Development Committee (2007−2009); • 25th Anniversary Committee (2008−2009); • Local Host Committee for ICPE 2009 (2008−2009); • Abstract Reviewer (2008−Present)

2004−2008

Member, Kappa Psi Pharmaceutical Fraternity Graduate Chapter, Providence, RI

PEER REVIEWER PLoS ONE Medical Care American Journal of Epidemiology British Medical Journal Journal of Clinical Epidemiology Effective Health Care Program of the Agency for Healthcare Research and Quality (AHRQ) Medicare & Medicaid Research Review Epidemiology Diabetes, Obesity, and Metabolism Diabetologia Journal of the European Academy of Dermatology and Venereology Pharmacoepidemiology and Drug Safety FDA Mini-Sentinel Project Annals of Internal Medicine JAMA Internal Medicine (Archives of Internal Medicine) Diabetes Research and Clinical Practice Journal of Diabetes Science and Technology Movement Disorders Clinical Therapeutics Journal of Managed Care Pharmacy Updated April 2014

Page 6 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

American Journal of Geriatric Pharmacotherapy Annals of Pharmacotherapy the Journal of Pharmacy Technology REFEREED PUBLICATIONS Submitted or in preparation (selected to represent recent work): 1. Amend KL, Koralek D, Dore DD. Occurrence of Osteonecrosis and Total Joint Replacement among Patients with Osteoarthritis. Submitted. 2. Michalopoulos E, Trivedi AN, Case B, Dore DD. Prescription Patterns and Costs Associated with Treatment of Acute Depressive Episodes Associated with Bipolar-I Disorder (BD-1) Among Commercially Insured Patients. In preparation. 3. Michalopoulos E, Trivedi AN, Case B, Dore DD. Prescription Patterns and Costs Associated with Treatment of Acute Manic Episodes Associated with Bipolar-I Disorder (BD-1) Among Commercially Insured Patients. In preparation. 4. Liang C, Seeger JD, Dore DD. Implications of Immortal Person-Time when Outcomes are Non-Fatal. Submitted. 5. Cooper AL, Dore DD, Kazis LE, Mor V, Trivedi AN. Predictors of High-Risk Prescribing among Elderly Medicare Advantage Beneficiaries. Provisionally Accepted, American Journal of Manage Care. 6. Cooper AL, Dore DD, Kazis LE, Mor V, Trivedi AN. Changes in Patient-Reported Health Status among Elderly Medicare Advantage Beneficiaries Exposed to High-Risk Drugs. In preparation. 7. Dore DD, Genberg BL, Lee Y, Rogers WH, Qato D, Wilson IB. Improving Measurement of Adherence to Medications in Health Insurance Claims Data: Deconstructing the Medication Possession Ratio. In preparation. 8. Genberg BL, Rogers WH, Lee Y, Qato D, Dore DD, Hutchins D, Brennan TA, Matlin O, Wilson IB. Prescriber and pharmacy variation in patient adherence to five medication classes. Submitted. 9. Dore DD, Berry, SD, Lee Y, Mor V. A Case-crossover Study of Age-, Gender-, and DoseSpecific Effects of Non-benzodiazepine Hypnotics on the Occurrence of Hip Fracture in Nursing Home Residents. Provisionally Accepted, BMJ. 10. Carman WJ, LaGuette J, Dore DD, Su S, McAfee AT. Venous Thromboembolism among Patients with Multiple Sclerosis: A Claims-based Study. Submitted. Published or in press 11. Dore DD, Ziyadeh N, Cai B, Clifford CR, Norman H, Seeger JD. A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data. BMC Pulm Med. 2014 Mar 19;14:47. doi: 10.1186/1471-2466-14-47.

Updated April 2014

Page 7 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

12. Cooper AL, Kazis LE, Dore DD, Mor V, Trivedi AN. Underreporting high-risk prescribing among Medicare Advantage plans: a cross-sectional analysis. Annals of Internal Medicine. 2013;159(7):456-62. doi: 10.7326/0003-4819-159-7-201310010-00005. 13. Dore DD. A Day in the Life of a Corporate Retail Pharmacist. Annals of Internal Medicine. 2013;159(5):366-7. doi: 10.7326/0003-4819-159-5-201309030-00014. 14. Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD. A pooled analysis of exenatide use and risk of acute pancreatitis. Curr Med Res Opin. 2013;29(12):1577-86. doi: 10.1185/03007995.2013.838550 15. Dore DD, Swaminathan S, Gutman R, Trivedi AN, Mor V. Erythropoietin-Stimulating Agents and Survival in End-Stage Renal Disease: Comparison of Payment Policy Analysis, Instrumental Variables, and Multiple Imputation of Potential Outcomes. J Clin Epidemiol. 2013;66(8 Suppl):S42-50. doi: 10.1016/j.jclinepi.2013.02.014. 16. Berry SD, Lee Y, Cai S, Dore DD. Non-benzodiazepine hypnotics and hip fractures in subgroups of nursing home residents. JAMA Intern Med. 2013;173(9):754-61. doi: 10.1001/jamainternmed.2013.3795. 17. Dore DD, Seeger JD, Chan KA. Incidence of Health Insurance Claims for Thyroid Neoplasm and Pancreatic Malignancy in Association with Exenatide Twice Daily: Signal Refinement Using Active Safety Surveillance. Therapeutic Advances in Drug Safety. 2012;3(4):157–164. DOI: 10.1177/ 2042098612446473 18. Dore DD, Liang C, Ziyadeh N, Norman H, Bayliss M, Seeger JD. Linkage of Routinely Collected Oncology Clinical Data with Health Insurance Claims Data—An Example with Aromatase Inhibitors, Tamoxifen, and All-Cause Mortality. Pharmacoepidemiology and Drug Safety. 2012;21 Suppl 2:29-36. doi: 10.1002/pds.3244. 19. Dore DD, Turnbull BR, Seeger JD. Vaccine Discontinuation and Switching Following Regulatory Interventions in Response to Rotavirus Vaccine Contamination with Porcine Circovirus DNA Fragments. Pharmacoepidemiology and Drug Safety. 2012;21(4):415-9. doi: 10.1002/pds.3217 20. Wang S, Linkletter C, Dore D, Mor V, Buka S, Maclure M. Age, antipsychotics, and risk of ischemic stroke in the Veteran’s Health Administration (VHA). Stroke. 2012;43(1):28-31. 21. Wang SV, Linkletter C, Maclure M, Dore DD, Mor V, Buka SL, Wellenius GA. Future cases as present controls to adjust for exposure-trend bias in case-only studies. Epidemiology. 2011;22(4):567-573 22. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD. A Cohort Study of Acute Pancreatitis in Relation to Exenatide Use. Diabetes, Obesity, & Metabolism. 2011;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x. 23. Dore DD, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiology and Drug Safety. 2011;20(2):209-13. doi: 10.1002/pds.2077.

Updated April 2014

Page 8 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

24. Dore DD, Norman H, Loughlin J, Seeger JD. Extended Case-Control Study Results on Thromboembolic Outcomes among Transdermal Contraceptive Users. Contraception. 2010;81(5):408-413. 25. Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical Antipsychotic Use and Risk of Fracture in Persons with Parkinson’s Disease. Movement Disorders. 2009;24(13):1941-1948. 26. Dore DD, Trivedi AN, Mor V, Lapane KL. Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction. Pharmacotherapy. 2009;29(7):775-783. 27. Dosa DM, Dore DD, Mor V, Teno JM. Frequency of Long-Acting Opioid Analgesic Initiation in Opioid-Naïve Nursing Home Residents. Journal of Pain and Symptom Management. 2009;38(4):515-521. 28. Daiello L, Ott, B, Lapane KL, Reinert S, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. American Journal of Geriatric Pharmacotherapy. 2009;7(2):74-83. 29. Dore DD, Seeger JD, Chan KA. Use of a Claims-Based Active Drug Safety Surveillance System to Assess the Risk of Acute Pancreatitis with Exenatide or Sitagliptin Compared to Metformin or Glyburide. Current Medical Research and Opinion. 2009;25(4):1019-1027. 30. Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA. Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Annals of Internal Medicine. 2009;150(1):9-18. 31. Lapane KL, Quilliam BJ, Dore DD. Roadblock on the Health IT Superhighway: E-Prescribing and the Controlled Substances Act. Journal of Opioid Management. 2007;3(4):181-184. 32. Dore DD, DiBello JR, Lapane KL. Telithromycin Use and Spontaneous Reports of Hepatotoxicity. Drug Safety 2007;30(8):697-703. 33. Caron MF, Dore DD, Min B, Kluger J, Boguk I, White CM. The Electrocardiographic and Blood Pressure Effects of the Ephedra Containing TrimSpa Thermogenic Herbal Compound in Healthy Volunteers. Pharmacotherapy 2006;26(9):1241-1246. 34. Dore DD, Larrat EP, Vogenberg FR, Principles of Epidemiology for Clinical and Formulary Management Professionals. Pharmacy and Therapeutics 2006;31(4):218-229. OTHER PUBLICATIONS 1. Dore DD. A day in the life of a corporate retail pharmacist (Letter in Response to Brock). Ann Intern Med. 2014;160(1):70. doi: 10.7326/L14-5000-1 2. Berry SD, Dore DD. Understanding drug effects in older people: the role of pharmacologyreply. JAMA Intern Med. 2013;173(20):1930-1. doi: 10.1001/jamainternmed.2013.9762. 3. Dore DD, Norman H, Seeger JD. Eligibility Criteria in Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System Users. Obstetrics & Gynecology 2009;114(1):175.

Updated April 2014

Page 9 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

4. Dore DD, Zierler S. Over-Reliance on Patient Information Sheets. American Journal of Medicine 2007;120(8):e3.

ACADEMIC RESEARCH FUNDING (Excludes Funding from Consulting Work) Ongoing Research Support 12/2012−12/2013

Principal Investigator, Study of non-invasive ventilation and mortality in amyotrophic lateral sclerosis (ALS). Funded by Biogen Idec. The objective of this study is to estimate the effect of non-invasive ventilation on the rate of mortality in patients with ALS.

5/1/12−9/30/2014

Investigator. Center on Systems, Outcomes & Quality in Chronic Disease & Rehabilitation (SOQCR), Providence VA Medical Center (PI: Peter Friedmann, MD, MPH). The research focus of the SOQCR is the evaluation of the multi-level influence of institutional and community-based health systems on the outcomes of chronic disease and rehabilitation.

7/1/12- 6/30/15

R01 HL111032-01A1 University of California, San Francisco / AHRQ Subcontract ($121,244), Dore (Site-PI) 1.00 AM, 0.20 SM “Outcomes to beta blockers after myocardial infarction in nursing home residents” This project uses the Minimum Data Set, Medicare Enrollment Records, and Medicare claims to estimate the effect of beta-blocker therapy after myocardial infarction on intended outcomes among long stay nursing home residents.

1/1/2013−6/30/2014 Co-mentor, 5K08HS017735-04 “Neglected By The Evidence: The Intersection Of Medical Complexity And Dementia” I am working with PI Lori Daiello, PharmD on a series of studies on the effects of discontinuing dementia treatments on exacerbation of dementia symptoms. 5/1/2012–5/30/2017 
Mentor, 2T32 AG023482-08A1 (PI: Vincent Mor, PhD) NIA This training grant proposal seeks to support the training of pre-doctoral trainees in Epidemiology, Health Services Research and Biostatistics. Role: Mentor

Pending Research Support R-1306-03844 Methods Grant Dore & Gutman (dual-PI) 1/1/2014−12/31/2015 PCORI $420,129 “Causal subgroup analysis in observational data with application to congestive heart failure in U.S. Veterans” This proposal is composed of two main objectives. The first is aimed at development and testing of methods for estimation of heterogeneous effects. In the second aim, we will also identify conditions that modify the effect size. R21 Number Pending Harvard Medical School Subcontract, Sarah Berry (PI) 9/1/2014−8/31/16 NIA Subcontract $150,000 (Total: $275,000) “Prediction Tool to Evaluate Hip Fracture Risk and Treatment in Nursing Home Residents”

Updated April 2014

Page 10 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

The proposed subcontract is pharmacoepidemiologic investigators via the use of a linked Medicare database of long-stay residents and methods for inference about the effects of medication use. Role: Site PI VA Merit IHX001279A Dore (PI) 7/1/2015−6/30/2015 VA HSR&D $1,041,450 “Whom does it harm? Causal Effects of Testosterone Replacement on Safety Outcomes” The proposed research is relevant to public health because it will inform physicians and regulators about the safety of testosterone replacement therapy, especially in older men with low-normal testosterone, so that the benefit-risk ratio of testosterone replacement in this population can be reasonably estimated. 1R21AG045316-01 Dore, David & Gutman, R (dual-PI) 2 years NIA $275,000 Effectiveness of Heart Failure Treatment in Multiply Chronically Ill Patients In this study, we will compare treatment with renin-angiotensin system inhibition and beta-blockers on mortality and hospitalization for heart failure among patients with high-risk, physical and psychological comorbidities. 5930 Methods Grant Dore & Gutman (dual-PI) 7/1/2013−6/30/2015 (Review delayed) PCORI $508,602 “Estimation of multi-treatment causal effects from observational data with application to diabetes mellitus.” In this project, we will develop and test analysis methods for comparing more than two potential treatments. Different methods will be evaluated for comparing unique treatments (e.g., three different medications) and separately for situations such as when we wish to know differences that result from different doses of the same drug or the use of several of treatments at the same time. Completed Research Support 2006−2007

AHRQ T32 Postdoctoral Fellow (PI: Vincent Mor, PhD). I was a post-doctoral fellow at the Center for Gerontology and Health Care Research at Brown University. In this capacity I worked on a number of published pharmacoepidemiologic studies and worked with Dr. Vincent Mor and Health Services Research Projects.

7/1/11−2/28/12

Investigator, Study of Physician-level influence on Adherence to Medications. Funded by CVS/Caremark (PI: Ira Wilson, MD, MSc). The analysis has 2 main goals: To separate variance in medication adherence into the following sources of variance: patient, physician, pharmacy, and possibly region of the state. Analyses will adjust for census-derived, block level sociodemographic data that will be obtained using methods that do not compromise patient confidentiality. A second goal of the analysis would be to look at the distribution of physician level variance to try to understand the shape of these distributions.

INVITED PRESENTATIONS 1. 2013. Dore DD. Case Studies in Post-marketing Drug Safety Evaluation. Department of Epidemiology, GlaxoSmithKline, Research Triangle Park, NC.

Updated April 2014

Page 11 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

2. 2013. Dore DD. Getting More From Your Trial Data Through Linkage with Administrative Data—A Pharmacoepidemiologist’s Perspective. Steering Committee Meeting, NIH Pelvic Floor Disorders Network Meeting, Providence, RI. 3. 2013. Dore DD. A Case-crossover Study of Age-, Gender-, and Dose-Specific Effects on Nonbenzodiazepine Hypnotics on the Occurrence of Hip Fracture in Nursing Home Residents. Seminar, Department of Epidemiology, Program in Public Health, Brown University 4. 2012. Dore DD. Research and Scholarship Opportunities in Pharmacoepidemiology. Western New England College of Pharmacy. 5. 2012. Dore DD. The Ortho Evra® Thromboembolism Study and Supplementary Data Collection to Address Bias in Studies using Health Insurance Claims Data. Invited Seminar. Department of Obstetrics and Gynecology, Alpert Medical School/Women and Infants’ Hospital. Providence RI. 6. 2011 Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Multi-study Drug Safety Assessment Program. Invited Seminar. Department of Population Medicine, Harvard Medical School, Boston, MA. 7. 2011 Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Multi-study Drug Safety Assessment Program. Invited Seminar. Harvard School of Public Health, Boston, MA. 8. 2011 Dore DD. Speaker: Exploring Nontraditional Career Paths, a panel discussion for BioMed Graduate Students and Postdocs featuring PhD’s working in industry, entertainment, and government. Brown University. 9. 2011 Dore DD. Use of Commercial Health Insurance Claims Data for Studying HIV/AIDS Care. Testimony to the Institute of Medicine Committee on Data Systems for Monitoring HIV Care. Washington, DC. 10. 2011 Anderson D, Dore DD. Ingenix Natural History of Disease Application—Uses for Pharmacoepidemiology. Seminar in Medical Bioinformatics. Stanford University Medical School, Palo Alto, CA. 11. 2011 Dore DD. Exenatide Use and Risk of Acute Pancreatitis: A Post-marketing Drug Safety Program Involving Safety Signal Refinement, Going Beyond Claims Data, and Mitigating Misclassification Bias and Confounding in a Distributed Data Model. Seminar, Section of Health Services, Policy, and Practice, Department of Community Health, Brown University, Providence, RI 12. 2009 Dore DD, Polinski J. Career Opportunities in Pharmacoepidemiology. Student Skills Workshop. International Society for Pharmacoepidemiology Annual Meeting (Poster). Providence, RI ABSTRACTS, CONFERENCE PRESENTATIONS, AND MISCELLANEOUS PRESENTATIONS 1. 2014 (SUBMITTED) Donnie P Funch, Anthony P Nunes, Yan Ding, Robin C Clifford, Nicholas J Everage, David D Dore. Comparison of Clinical Measures between those with and without a Diagnosis of Diabetes among Patients Prescribed Antidiabetic Drugs within the Humedica EHR Database.

Updated April 2014

Page 12 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

2. 2014 (SUBMITTED) Donnie P Funch, Douglas S Ross, Betsey M Gardstein, Heather S Norman, Lauren A Saunders, Atheline Major-Pedersen, Sofia II Kring, David D Dore. Performance of Claims-Based Algorithms for Identifying Thyroid Cancer in Commercial Health Plan Enrollees Receiving Antidiabetic Therapies. 3. 2014 (SUBMITTED) Florence T Wang, Fei Xue, MD, Eva Ng, Cathy W Critchlow, David D Dore. Performance of an algorithm for identifying serious dermatologic adverse events in commercial health plan claims data. 4. 2014 (SUBMITTED) Florence T Wang, Fei Xue, Eva Ng, Cathy W Critchlow, David D Dore. Performance of an algorithm for identifying primary hypocalcemia in commercial health plan claims data. 5. 2014 Danilack VA, Triche EW, Dore DD, Muri JH, Phipps MG, Savitz DA. Labor induction and cesarean delivery: Implications in the choice of comparison group. 27th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research (SPER). Seattle, WA 6. 2014 Danilack VA, Triche EW, Dore DD, Muri JH, Phipps MG, Savitz DA. Labor induction and cesarean delivery: Implications in the choice of comparison group. 47th Annual Meeting, Society for Epidemiologic Research (SER), Seattle, WA 7. 2014 Nunes AP, Yu S, Kurtyka KM, Senerchia C, Hill JM, Brodovicz KG, Radican L, Engel SS, Calvo SR, Dore DD. Natural language processing of clinical notes in electronic health records to improve capture of hypoglycemia. Late Breaking Abstract. American Diabetes Association, 74th Scientific Sessions, San Francisco, CA. 8. 2013 Critchlow C, Curtis JR, Dore DD, Rothman KJ, Pedersen L, Sprafka M, Staffa J, Sturkenboom M, Xue F. Post-Marketing Pharmacoepidemiologic Database Studies To Assess Drug Safety. Ninety-minute symposium on best practices for post-marketing drug safety studies. International Society for Pharmacoepidemiology Annual Meeting. Montreal, Quebec, Canada 9. 2013 Dore DD, Berry SD, Lee Y, Mor V. A Case-Crossover Study of Age-, Gender-, and Dose-Specific Effects of Non-Benzodiazepine Hypnotics on the Occurrence of Hip Fracture in Nursing Home Residents. International Society for Pharmacoepidemiology Annual Meeting (Oral). Montreal, Quebec, Canada 10. 2013 Liang C, Turnbull BR, Skerry KE, Appenteng K, Motsko SP, Dore DD. Algorithms To Identify Pancreatic Cancer and Thyroid Neoplasm from Health Insurance Claims Data. International Society for Pharmacoepidemiology Annual Meeting (Poster). Montreal, Quebec, Canada 11. 2013 Krishnaswamy N, Zullo A, Dore DD. A Systematic Review of the Adverse Effects of Atypical Antipsychotics in the Elderly Population. International Society for Pharmacoepidemiology Annual Meeting (Poster). Montreal, Quebec, Canada 12. 2013 Joyce N, Wellenius G, Dore DD, Zachariah J. Changes in rates of pharmacotherapy for children with familial hypercholesterolemia between 2004 and 2010. Society for Epidemiologic Research Annual Meeting. Boston, MA. 13. 2013 Genberg BL, Rogers WH, Lee Y, Qato D, Dore DD, Hutchins D, Wilson IB. Prescriber and pharmacy variation in patient adherence to five drug classes. AcademyHealth Annual Updated April 2014

Page 13 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

Research Meeting. Baltimore, MD.. 14. 2013 Cooper AL, Dore DD, Kazis LE, Mor V, Trivedi AN. Changes in Patient-Reported Health Status among Elderly Medicare Advantage Beneficiaries Exposed to High-Risk Drugs. AcademyHealth Annual Research Meeting. Baltimore, MD.. 15. 2013 Gutman R, Dore DD, Swaminanthan S, Mor V. Robust Estimation of Causal Effects of Erythropoiesis-stimulating Agents on Mortality. International Biometric Society, Eastern Mediterranean Regional Meeting (Roee Gutman, PhD, Presenter) 16. 2013 Joyce N, Dore DD, Cai S, Makineni R, Intrator O, Dosa DM. Patterns In Naive Opioid Initiation And Reported Daily Pain Among Veterans In Community Living Centers (CLCs) Between 2004 And 2009. American Geriatrics Society. Grapevine, TX.. 17. 2012 Berry SD, Lee Y, Cai S, Mor V, Dore DD. Non-benzodiazepine hypnotics increase the risk of hip fracture in nursing home residents. The American Society for Bone and Mineral Research Annual Meeting. Minneapolis, MN (Oral, Sarah Berry, MD, MPH, Presenter) 18. 2012 Everage NJ, Dore DD, Seeger JD. Validate in One Data Source and Apply Results to Another – What Could Possibly Go Wrong? Assumptions behind Addressing Outcome Misclassification in Distributed Data Models. Ninety-minute instructional symposium. International Society for Pharmacoepidemiology Annual Meeting. Barcelona, Spain 19. 2012 Amend KL, Koralek D, Dore DD. Occurrence of Osteonecrosis and Total Joint Replacement among Patients with Osteoarthritis. International Society for Pharmacoepidemiology Annual Meeting (Oral, K. Amend). Barcelona, Spain 20. 2012 Wang FT, Xue F, Perhanidis J, Ng E, Critchlow C, Dore DD. Bisphosphonate Route of Administration and Select Health Outcomes of Interest (HOIs) among Women with Postmenopausal Osteoporosis. International Society for Pharmacoepidemiology Annual Meeting (Poster). Barcelona, Spain 21. 2012 Liang C, Seeger JD, Dore DD. Implications of Immortal Person-Time when Outcomes are Non-Fatal. International Society for Pharmacoepidemiology Annual Meeting (Poster). Barcelona, Spain 22. 2012 Session co-moderator: “Hormones: Can't Live with Them, Can't Live without Them.” International Society for Pharmacoepidemiology Annual Meeting (Poster). Barcelona, Spain 23. 2012 Wang FT, Xue F, Perhanidis J, Ng E, Critchlow C, Dore DD. Exploratory Analysis to Improve Identification of Early Users of Prolia® in a Commercial Insurance Database. International Society for Pharmacoepidemiology Annual Meeting (Poster). Barcelona, Spain 24. 2012 Carman WJ, Manthripragada A, O’Malley C, Dore DD. Cohort Entry Criteria and Comorbidities in a Claims-Based Male Osteoporotic Population. International Society for Pharmacoepidemiology Annual Meeting (Poster). Barcelona, Spain 25. 2011 Session co-moderator: “Fractures – Give Us a Break.” International Society for Pharmacoepidemiology Annual Meeting. Chicago, IL. 26. 2011 Wang S, Mor V, Maclure M, Dore, DD, Linkletter C, Buka S. Treatment with antipsychotics and risk of myocardial infarction in the Veteran’s Health Administration (VHA): A Updated April 2014

Page 14 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

case-case time control study. International Society for Pharmacoepidemiology Annual Meeting. Chicago, IL. (Oral, S. Wang). *Winner Stanley A. Edlavitch Award for the Best Student Abstract (S. Wang) 27. 2011 Wang S, Dore DD, Mor V, Maclure M, Linkletter C, Buka S. Antipsychotics and risk of stroke among elderly and non-elderly in the Veterans Health Administration: A case-case time control study. International Society for Pharmacoepidemiology Annual Meeting. Chicago, IL (Oral, S. Wang). 28. 2011 Wang S, Linkletter C, Maclure M, Dore DD, Mor V, Buka S, Wellenius G. Future cases as present controls: Methods to adjust for exposure-time trends. International Society for Pharmacoepidemiology Annual Meeting. Chicago, IL. 29. 2011 Thyagarajan V, Glass R, Rodgers K, Quinlan S, Holick CN, Rosillon D, Lu E, Dore DD, Acosta C, Seeger JD. Validity of Current Procedural Terminology Codes for Rotavirus Vaccination in Two Commercially-Insured US Populations. International Society for Pharmacoepidemiology Annual Meeting (Oral, V. Thyagarajan). Chicago, IL. 30. 2011 Lin ND, Seeger JD, Ng E, Dore DD. Residual covariate imbalance following subclassification on propensity score in comparison groups with large differences in sample size. International Society for Pharmacoepidemiology Annual Meeting (Poster). Chicago, IL. 31. 2011 Lin ND, Seeger JD, Ng E, Dore DD. Safety surveillance study of abatacept therapy among patients with rheumatoid arthritis. International Society for Pharmacoepidemiology Annual Meeting (Oral, N. Lin). Chicago, IL. 32. 2011 Dore DD, Turnbull BR, Seeger JD. Effects of Regulatory Interventions in Response to Rotavirus Vaccine Contamination with Porcine Circovirus DNA Fragments. International Society for Pharmacoepidemiology Annual Meeting (Poster). Chicago, IL. 33. 2011 Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD. A Pooled Analysis of Cohort Studies Comparing Risk of Acute Pancreatitis among Initiators of Exenatide and Other Antihyperglycemic Drugs in Two Commercial Health Insurance Claims Databases. International Society for Pharmacoepidemiology Annual Meeting (Poster). Chicago, IL. 34. 2011 Dore DD, Ziyadeh N, Cai B, Clifford CR, Norman H, Seeger JD. Identification of Asthma and Chronic Obstructive Pulmonary Disease among Initiators of Long-Acting βAgonists in Health Insurance Claims Data. International Society for Pharmacoepidemiology Annual Meeting (Poster). Chicago, IL. 35. 2011 Buikema A, Davis E, Fan Y, Standaert B, Acosta, Dore DD. Rotavirus Vaccine Compliance and Completion Among Infants in Managed Care. 45th National Immunization Conference (Poster). Washington, DC. 36. 2010 Bloomgren GL, Wenten M, Dore DD, Hussein M, Pelletier EM, Smith DB, Noel RA, Braun DK, Seeger JD. Retrospective Cohort Studies of the Risk of Acute Pancreatitis: Initiators of Exenatide BID Compared to Other Antidiabetic Drugs in Two Commercial US Health Insurance Claims Databases. European Association for the Study of Diabetes Annual Meeting (Oral, D. Dore). Stockholm, Sweden

Updated April 2014

Page 15 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

37. 2010 Wang SV, Linkletter C, Maclure M, Dore DD, Mor V, Buka S, Wellenius G. Application & Extension of Self-Controlled Designs (for Pharmacoepidemiologists). International Society for Pharmacoepidemiology Annual Meeting (Oral, S. Wang). Brighton, England 38. 2010 Dore DD, Bloomgren GL, Wenten M, Noel RA, Braun DK, Seeger JD. Final Results from a Retrospective Cohort Study of the Incidence of Acute Pancreatitis in Exenatide Twice Daily Initiators Compared to Other Antidiabetic Drug Initiators. International Society for Pharmacoepidemiology Annual Meeting (Poster). Brighton, England 39. 2009 Dore DD, Bloomgren GL, Patterson RE, Quinn SG, Hoffman C, Chaudhry S, Noel RA, Braun DK, Seeger JD. Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators: A Retrospective Cohort Study. International Society for Pharmacoepidemiology Annual Meeting (Oral, D. Dore). Providence, RI 40. 2009 Dore DD, Seeger JD, Chan KA. Active Safety Surveillance of the Risk of Acute Pancreatitis Associated with Exenatide or Sitagliptin Compared to Metformin or Glyburide. International Society for Pharmacoepidemiology Annual Meeting (Poster). Providence, RI 41. 2009 Dore DD, Chaudhry S, Quinn SG, Seeger JD. Medical Record Abstraction to Supplement Covariate Data in Health Insurance Claims: the Case of Diabetes and Acute Pancreatitis. International Society for Pharmacoepidemiology Annual Meeting (Poster). Providence, RI 42. 2009 Dore DD, Hoffman C, Quinn SG, Chaudhry S, Seeger JD. Positive Predictive Value of Commercial Health Insurance Claims Data for Identifying Acute Pancreatitis in Patients with Diabetes Mellitus. International Society for Pharmacoepidemiology Annual Meeting (Oral, D. Dore). Providence, RI 43. 2009 Dore DD, Norman H, Hoffman C, Wong J, Seeger JD. Extended Results on the Risk of Venous Thromboembolism, Myocardial Infarction, and Stroke in Users of Transdermal Norelgestromin/Ethinyl Estradiol. International Society for Pharmacoepidemiology Annual Meeting (Oral, D. Dore). Providence, RI 44. 2009 Dore DD, McAfee AT, Woo RK, Seeger JD. Enhanced Oncology Applications of Health Insurance Claims Data through Clinical Data Linkage. International Society for Pharmacoepidemiology Annual Meeting (Poster). Providence, RI 45. 2009 Bloomgren GL, Dore DD, Patterson RE, Noel RA, Braun DK, Seeger JD. Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators: A Retrospective Cohort Study. American Diabetes Association Annual Scientific Meeting (Oral, G. Bloomgren). New Orleans, LA 46. 2008 Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical Antipsychotic Use and Risk of Fracture in Persons with Parkinson’s Disease (Oral Presentation). International Society for Pharmacoepidemiology Annual Meeting (Oral, D. Dore). Copenhagen, Denmark 47. 2008 Dore DD, Trivedi AN, Mor V, Lapane KL. Timing of Thiazolidinedione Initiation and Risk of Acute Myocardial Infarction. International Society for Pharmacoepidemiology Annual Meeting (Poster). Copenhagen, Denmark

Updated April 2014

Page 16 of 17

Curriculum Vitae

David D. Dore, PharmD, PhD

48. 2008 Dore DD, Loughlin J, Jones M, Zhu S, Chaudhry SB, Seeger JD. Risk of Ventricular Arrhythmia in Association with Atomoxetine Use in Adults. International Society for Pharmacoepidemiology Annual Meeting (Poster). Copenhagen, Denmark 49. 2007 Dore DD, Lapane KL, Mor V, Trivedi AN, Weinstock MA. Effectiveness of Statins for Prevention of Keratinocyte Carcinomas. International Society for Pharmacoepidemiology Annual Meeting (Oral, D. Dore). Quebec City, Quebec, Canada 50. 2007 Dore DD, Lapane KL. Prevalence and Correlates of Stimulant Medication Use in U.S. Adults. AcademyHealth Annual Research Meeting (Poster). Orlando, FL 51. 2007 Dore DD, Dosa DM, Mor V, Teno JM. Potentially Inappropriate Initiation of Long-Acting Narcotic Analgesics in Nursing Home Residents. Agency for Health Care Research and Quality Fellows Meeting (Poster). Orlando, FL 52. 2007 Dore DD. Effectiveness of Statins for Prevention of Keratinocyte Carcinoma (Research Seminar). Center for Gerontology and Health Care Research, Brown Medical School 53. 2005 Dore DD, DiBello JR, Lapane KL. Evaluating Telithromycin-Related Hepatotoxicity: An Application of the Case-Control Design to Spontaneous Report Data. International Society for Pharmacoepidemiology Annual Meeting (Oral, D. Dore). Lisbon, Portugal 54. 2006 Dore DD. Prevalence and Determinants of Atypical Antipsychotic Use in Nursing Homes. Agency for Health Care Research and Quality Fellows Meeting (Oral). Seattle, WA 55. 2005 Dore DD. Navigating Medicare Part D: An Impossible Dream? Center for Gerontology and Health Care Research, Brown Medical School 56. 2004 Dore DD, Boguk I, Caron MF. What are the Effects of a Dietary Weight Loss Supplement Containing Ephedrine and Caffeine on Heart Rate and QT Interval in Healthy Volunteers? American Society of Health-System Pharmacists Annual Meeting (Poster). Las Vegas, NV 57. 2004 Dore DD, Bunz TJ, Kogut SJ. Drug therapy for Alzheimer’s disease: Persistence on Cholinesterase Inhibitors Measured using Medicaid Pharmacy Claims Data. American Pharmacists Association Annual Meeting (Oral, D. Dore), Seattle, WA 58. 2004 Bunz TJ, Dore DD, Kogut SJ. Persistence after cholinesterase therapy change in a Medicaid dataset. American Pharmacists Association Annual Meeting (Poster). Seattle, WA 59. 2003 Dore DD, Responsible use of Medications at the End of Life. Home and Hospice Care of Rhode Island, Pawtucket, RI 60. 2003 Dore DD, The Role of Atypical Antipsychotics in the Management of Dementia. Home and Hospice Care of Rhode Island, Pawtucket, RI 61. 2003 Dore DD, Bunz TJ. The Influence of Concomitant use of Anticholinergics on Persistence with Cholinesterase Inhibitors in Alzheimer’s Disease. Seminar in Pharmacoepidemiology and Pharmacoeconomics; University of Rhode Island College of Pharmacy, Kingston, RI

Updated April 2014

Page 17 of 17